• The program began with a robotic left internal mammary artery (“LIMA”) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra advanced robotic surgical system from SS Innovations.
• SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025.
• The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines.
• SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets.

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery LIMA take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.

“We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region,” the company wrote in a LinkedIn post (https://ibn.fm/TTTdR). “At SS Innovations International, Inc. we remain committed to enabling hospitals and surgical teams across the country to bring advanced, affordable robotic surgery to more patients, in more places.”

The Ahmedabad deployment adds another cardiac program to an installed base that is increasingly being used across specialties and geographies. The announcement comes shortly after SS Innovations reported that 238 SSi Mantra systems had been installed as of September 8, compared with 168 at the end of 2025. That represents a 42% increase in the installed base during the period.

Procedure volumes have grown more rapidly. The company reported 14,103 cumulative multi-specialty procedures using SSi Mantra as of September 8, up from 7,885 at the end of 2025, an increase of 79%. Approximately 1,500 physicians have been trained on the system, which has been used for more than 170 different types of surgical procedures.

The figures provide a measure of the operating base SS Innovations has established in India while the company works to replicate that model internationally. In July, SS Innovations launched a robotic cardiac surgery program at La Fundación Cardiovascular de Colombia in Bucaramanga. The program included Colombia’s first Totally Endoscopic Beating-Heart Bypass Surgery performed using SSi Mantra.

In August, Kings Hospital Colombo installed the first SSi Mantra system in Sri Lanka. The company subsequently reported the country’s first robotic-assisted cardiac surgery using the platform, followed by more than 25 additional robotic procedures during the system’s first three weeks of operation.

With the Sri Lankan installation, SS Innovations said the SSi Mantra’s installed base had reached 12 countries.

The company is also extending the platform into pediatric procedures. On August 14, SSi Mantra and 5-millimeter instruments were used for a robotic pyeloplasty on a 45-day-old infant at Hindusthan Hospital in Coimbatore, India. SS Innovations reported 258 cumulative pediatric robotic surgeries as of August 31.

Telesurgery represents another developing application. As of August 31, the company reported 188 robotic telesurgeries using SSi Mantra. One July procedure connected surgeons at Hospital Internacional de Colombia in Bucaramanga with a patient at Mohak Bariatrics and Robotics in Indore, India, across more than 13,600 miles of fiber-network distance.

In September, SSi Mantra was also used for what the company described as the first telesurgery within the Philippines, connecting Pampanga and Cotabato across approximately 1,710 kilometers.

SS Innovations is positioning SSi Mantra around both advanced surgical capabilities and accessibility. The platform is a modular system with three to five robotic arms, a 3D 4K visualization system and more than 40 types of robotic endo-surgical instruments, according to the company. Its product range also includes the SSi Mudra instrument portfolio and the portable MantrAsana tele-surgeon console.

The next major development area is regulatory expansion. SS Innovations submitted its SSi Mantra 510(k) premarket notification to the U.S. Food and Drug Administration in December 2025. The company now expects the FDA review to be completed by the end of the first quarter of 2027. It also believes the SSi Mantra can obtain European Union CE marking by the end of 2026.

For more information, visit the company’s website at www.SSInnovations.com.

NOTE TO INVESTORS: The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

• The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS.
• What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism.
• Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated.

A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS, clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate.

The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that was not possible without FDA clearance.

According to the announcement, the upcoming study will be randomized, double blind and placebo controlled, a design considered the gold standard for testing whether a new drug actually works. Researchers plan to measure efficacy, safety and tolerability in people living with MS, tracking both clinical symptoms and radiological changes in the brain. Site selection and other trial start-up activities are already underway, with patient enrollment expected to begin as soon as possible.

What sets Lucid-MS apart from most existing MS therapies is its mechanism. The compound is designed to protect nerve cells by inhibiting demyelination, the breakdown of the fatty sheath that insulates nerve fibers. This sheath is critical in allowing the brain to communicate effectively with the rest of the body. Most currently approved MS drugs instead work by suppressing or modulating the immune system, an approach that can leave patients vulnerable to infections and other side effects.

Lucid-MS targets an enzyme called peptidyl arginine deiminase 2, or PAD2, which has been implicated in the breakdown of myelin when its activity is increased. In preclinical models, the compound demonstrated the ability to protect the myelin sheath from this type of damage, supporting its potential as a neuroprotective approach in MS. The company notes that the compound also was not found to suppress the immune system, distinguishing its proposed approach from most currently marketed treatments.

Before reaching this milestone, Lucid-MS completed phase 1 clinical trials in healthy human volunteers. Quantum BioPharma reported that the drug showed a favorable safety profile and was well tolerated in that earlier testing, an important precondition for moving into a patient population. The underlying science behind the compound has also been published in peer-reviewed journals, including the Journal of Medicinal Chemistry and the Proceedings of the National Academy of Sciences.

Quantum BioPharma also disclosed its financial position alongside the clinical update. The company reported approximately $10 million in cash, digital assets and liquid investments as of June 30, 2026, providing some runway as it moves into the more resource-intensive phase 2 stage of development.

There is no cure for multiple sclerosis today, and the disease remains a leading cause of neurological disability among young adults. The FDA’s clearance does not guarantee that Lucid-MS will ultimately prove effective or reach the market; all drug candidates that begin clinical trials do not receive final approval. Phase 2 testing exists specifically to answer the question of a drug’s effectiveness and safety, gathering real-world data on how the drug performs against a placebo in an actual patient population.

However, for a company still in the clinical stage of development, an FDA clearance represents significant forward momentum. Investors and patients alike will likely be watching for updates on site activation, enrollment progress and eventual trial data as Quantum BioPharma works to advance a treatment approach it believes is fundamentally different from what is currently available.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• In today’s AI space, the holdup in growing the AI space is no longer chips but electricity.
• Azio AI’s strategy centers on securing power first, then layering compute capacity on top of it.
• The company frames its approach as full spectrum, selling GPU systems, hosting AI and high-performance computing workloads, and generating the power that keeps all of it running.

Every new AI model announced this year needs somewhere to run, and increasingly, that somewhere does not yet exist. Azio AI Holdings (NASDAQ: AZIO) is committed to closing that gap, building the data centers, GPU systems and power infrastructure that turn AI ambition into working compute.

Once upon a time, the bottleneck holding back the industry was chips, but that has changed. In today’s AI space, the holdup is electricity. Goldman Sachs Research estimates that U.S. data center power demand will climb from 31 gigawatts in 2025 to 41 gigawatts in 2026 and 66 gigawatts in 2027. That forecast is based on U.S. data center capacity doubling to about 95 gigawatts by the end of 2027.

Meeting that curve requires new construction at a pace the power grid was not built for. Goldman Sachs analysts expect data center capacity additions to jump to 13.6 gigawatts in 2026 and 36.3 gigawatts in 2027, compared with just 6.4 gigawatts added in 2024. Securing power for a site rather than securing GPUs has become the harder problem for developers to solve.

Spending is following that demand. The International Data Corporation projects global AI infrastructure spending will reach $487 billion in 2026 and surpass more than a trillion dollars by 2029. That growth has pulled a wave of new entrants into data center development, power generation and GPU hosting.

I would remove reference to me being President and updating numbers to 512 GPU units of pipeline sales, the sales amount and this new figure can be found in our latest PR from today. AZIO AI Holdings is an integrated compute infrastructure platform, spanning GPU and compute system sales, energy-backed AI hosting and company-operated Bitcoin mining. Led by an experienced executive team, including CEO and chair Chris Young with CFT Jason Maddox, the company follows a strategy focused on securing power first, then layering compute capacity on top of it.

That strategy is playing out in south Texas, where the company controls more than 548 acres of land engineered for up to 500 megawatts of behind-the-meter power capacity. Behind-the-meter power comes from generation built directly on site, letting a developer bypass years-long utility interconnection queues. The company’s most recent announcement unveiled the official name of the first stage of this project: Atlas One. 

Azio AI Holdings has secured approximately 11 megawatts of behind-the-meter natural gas power at that site and activated about 6 megawatts for an initial workload. It has also signed a master services agreement with AT&T for dedicated fiber connectivity, committing roughly 2.4 million dollars to the project.

On the hardware side, Azio AI Holdings has agreed to sell up to 512 NVIDIA HGX B300 GPU systems to Power Champion Investment Limited, in a deal the company estimates could be worth approximately $307 million. This agreement builds on earlier hosting agreements the two companies signed in July and earlier this month. 

The company frames its approach as full spectrum, selling GPU systems, hosting AI and high-performance computing workloads, and generating the power that keeps all of it running. That combination is meant to let Azio AI participate across multiple parts of the AI compute value chain rather than depending on a single hardware transaction or contract.

Azio AI Holdings still has work ahead to convert its land, power and hardware agreements into contracted, revenue-generating AI hosting capacity. The company has noted that its planned 500 megawatt buildout depends on additional financing, permitting and customer commitments. Even so, the company’s movement reflects a broader shift underway across the AI industry, where physical infrastructure has become as important as the models running on top of it. As compute demand keeps outpacing available power, companies that can deliver both are positioning themselves at the center of the buildout.

For more information, visit www.AzioAI.ai.

NOTE TO INVESTORS: The latest news and updates relating to AZIO are available in the company’s newsroom at https://ibn.fm/AZIO

Disseminated on behalf of SuperQ Quantum Computing Inc. and may include paid advertisements.

• SuperQ has commercialized its Super(TM) hybrid quantum and high-performance computing platform while advancing Super OS(TM) and the Super Nova(TM) hybrid quantum computer for data center, enterprise and secure on-site deployment.
• The company addresses multiple commercial applications through a portfolio spanning advanced optimization, post-quantum cybersecurity, consumer-facing quantum computing and tactical decision-support technology.
• SuperQ is expanding into U.S. defense and dual-use markets through the Canada and Q-Branch Dual-Use Accelerator and conducted a live operational field demonstration at the Bush Combat Development Complex in August 2026.
• The company secured a commercial agreement with AI Financial Corporation in May 2026 covering deployment of SuperPQC(TM) post-quantum security and integration of Super(TM) hybrid computing into digital asset infrastructure.
• SuperQ is pursuing international commercialization through activities spanning Canada, the U.S., Middle East, Asia and Europe, supported by its expanding Super Hub network and government-backed market-entry initiatives.

SuperQ Quantum Computing (CSE: QBTQ) (OTCQB: QBTQF) is a quantum and supercomputing company focused on reducing the technical and financial barriers to commercial adoption of advanced computing. The company combines quantum computing with classical high-performance computing to address complex optimization, cybersecurity and decision-making challenges for enterprises, governments and research institutions.

SuperQ’s approach is centered on making advanced computational resources more accessible and commercially practical through an integrated ecosystem of software, hardware and AI-driven technologies. The company is developing solutions intended to move quantum computing beyond specialized research environments and into practical enterprise, institutional and consumer applications.

Through its technology development and expanding international ecosystem, SuperQ is pursuing broader adoption of quantum and supercomputing across commercial, government and research environments. The company is also establishing regional hubs to provide access, training and expert guidance around emerging computing technologies.

SuperQ Quantum is headquartered in Canada, with a growing international presence particularly in the U.S., Middle East and Asia.

Products and Technology

Super(TM) Platform

Super(TM) is SuperQ’s commercialized hybrid quantum and supercomputing platform. The platform uses proprietary AI agents, called Super Autopilots, to autonomously build and execute solutions to complex optimization and cybersecurity problems. Its Super Optimizer capabilities span problem modeling and decomposition, mathematical optimization, AI model optimization, GPU computing, gate-based quantum computing and quantum annealing, along with the interpretation and visualization of results.

SuperQ is applying the platform to complex optimization and decision-making challenges across industries including logistics, energy, healthcare, transportation and manufacturing. The company also provides professional services to support product deployment and help organizations model and solve industry-specific challenges using the platform.

SuperPQC(TM)

SuperPQC(TM) is the company’s post-quantum cybersecurity suite, designed to assess cryptographic vulnerabilities and support migration toward quantum-resistant security. In May 2026, SuperQ announced a commercial agreement with AI Financial Corporation to deploy SuperPQC(TM) across its technology stack and integrate Super(TM) hybrid quantum computing into its digital asset infrastructure.

Super Edge(TM)

Super Edge(TM) extends the company’s technology into tactical and distributed operating environments. In August 2026, SuperQ deployed the technology during a live operational field demonstration at the Bush Combat Development Complex at Texas A&M University’s RELLIS Campus, where Super Edge(TM) and the Super(TM) platform were evaluated for real-time decision support, dynamic route optimization, post-quantum secured communications and edge-to-command integration.

ChatQLM(TM)

ChatQLM(TM) is SuperQ’s consumer-facing application powered by its proprietary Quantum Leveraged Model technology. The application combines conversational AI with access to quantum and high-performance computing, allowing users to describe complex problems in natural language while the system translates those requests into computational models and routes them to appropriate computing resources.

ChatQLM(TM) includes general AI functionality and quantitative decision-making applications alongside access to quantum simulators, quantum computers, visual quantum programming and educational resources. Through ChatQLM(TM), SuperQ is seeking to make quantum and supercomputing capabilities accessible to consumers without requiring specialized technical expertise.

Super OS(TM)

Super OS(TM) is an operating system under development to unify quantum and supercomputing for data center and enterprise deployment. It is being designed as an orchestration layer across heterogeneous computing infrastructure, enabling interoperability among classical CPUs, GPUs and quantum processing units. Super OS(TM) is intended to run on both SuperQ’s own hardware and supported third-party quantum computers.

Super Nova(TM)

Super Nova(TM) is SuperQ’s in-development modular hybrid quantum computer designed to run Super OS(TM) natively. Its proposed architecture combines quantum and classical processing through modular compute stacks that can be added or removed based on deployment requirements. SuperQ is targeting the technology for data center, enterprise and secure on-site deployments.

Super Hub

Super Hub is a global network designed to reduce technical and financial barriers to advanced technologies by providing physical access points to powerful remote hybrid computing systems across international borders. Located near communities worldwide, these experience zones are intended to host masterclasses, webinars, workshops and hackathons while supporting dedicated quantum technology interest groups. SuperQ serves as a catalyst for Super Hub locations to scale a global, decentralized model inspired by AT&T Bell and other leading laboratories, creating collaborative spaces where international community members can meet and develop solutions to complex global challenges. The network includes Canada’s first Quantum Super Hub in Lethbridge, eight hubs across Alberta and Asia’s first Super Hub at Sharjah Research Technology and Innovation Park’s SoiLAB in the UAE, with further international expansion planned across Asia.

Market Opportunity

SuperQ is targeting commercial opportunities spanning enterprise computing, post-quantum cybersecurity, defense and dual-use technology. According to figures cited by the company in July 2026, global private venture capital investment in defense technology reached a record $49.9 billion across 966 deals, nearly doubling year over year. The company also cited the U.S. dual-use venture market at $49 billion and the global GovTech dual-use platform market at $24.7 billion in 2025.

SuperQ further reported that the U.S. Department of Defense committed more than $17.5 billion in 2025 to emerging technologies including quantum computing and post-quantum cybersecurity. The company is engaging this market through the Canada and Q-Branch Dual-Use Accelerator, Fed Supernova 2026 and its August 2026 live operational demonstration at the Bush Combat Development Complex.

International expansion extends to Europe, where company materials identify the €22 million Quantum Spain initiative and €43 million Vall de la Quàntica program as investments supporting Barcelona’s quantum and deep-tech ecosystem. SuperQ was selected for a Canadian government-backed Deep Tech Innovation Mission to Barcelona, where it intends to showcase applications of its technology for mobility, decentralized energy, smart-city planning and other infrastructure challenges.

Leadership Team

Dr. Muhammad Ali Khan, Founder, Chief Executive Officer and Board Chair, is a Silicon Valley entrepreneur, technology executive and scientist with more than 20 years of experience spanning artificial intelligence, quantum computing and optimization in industry and academia. He has built and scaled private and public companies in Canada, the San Francisco Bay Area and the UAE and previously worked at universities around the world after graduating from the University of Cambridge. A Rhodes Scholar, Cambridge Commonwealth Scholar, Vanier Scholar and Killam Scholar, Dr. Khan has also advised and invested in startups and regularly participates in major technology conferences.

Krishna Ganesh, Chief Operating Officer and Director, is a seasoned data scientist, entrepreneur and technology consultant with experience in generative AI and supply chain applications. His background includes work as a Big Four technology consultant, and he serves on SuperQ’s board alongside his operational leadership responsibilities.

Manoj Joseph, Chief Business Officer and Director, is an enterprise business leader focused on business model innovation, cross-border market expansion and strategic partnerships. His experience includes B2B enterprise sales, partnership development and community building, and he also serves as a director of SuperQ.

For more information, visit the company’s website at https://www.superq.co.

NOTE TO INVESTORS: The latest news and updates relating to QBTQF are available in the company’s newsroom at https://ibn.fm/QBTQF

• In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed.
• Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
• Quantum BioPharma’s Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2.

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate: Lucid-MS.

Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Global prevalence rose from about 2.3 million people in 2013 to roughly 2.8 million in 2020 and had climbed to an estimated 2.9 million by 2023.

In the United States alone, close to one million people are living with the disease. A landmark study published in the journal “Neurology” found the figure was more than double what had previously been assumed for decades. The disease typically strikes people in their 20s and 30s, with women being diagnosed at roughly twice the rate of men.

The symptoms of MS can be unpredictable and wide ranging. They include fatigue, vision problems, numbness, balance and coordination trouble, and cognitive changes, all stemming from damaged communication between the brain and the rest of the body. Because the disease can progress differently in every patient, diagnosis and treatment planning remain genuinely difficult for physicians.

Most currently available therapies fall into a category called disease-modifying therapies, and the majority of these treatments work by suppressing or modulating the immune system. Interferons, glatiramer acetate and newer monoclonal antibodies are among the most widely prescribed options, and research shows these drugs can meaningfully reduce relapse rates for people with relapsing forms of the disease.

But that same body of research points to real limitations. Injectable immunomodulatory therapies suffer from poor long-term adherence, with roughly half of patients discontinuing treatment within the first year, according to the same published review. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.

That gap between managing relapses and actually protecting nerve tissue is where newer approaches are working to make progress. Researchers are increasingly interested in neuroprotective and remyelinating strategies, ones that aim to preserve or restore the myelin sheath itself rather than only calming the immune system’s attack on it.

Quantum BioPharma’s Lucid-MS candidate fits into that emerging category. Rather than suppressing immune activity, the compound is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2, which when overactive has been linked to myelin breakdown. Quantum reports that in preclinical animal studies, the compound prevented myelin degradation, and findings from that research have appeared in peer-reviewed outlets, including the Journal of Medicinal Chemistry and Proceedings of the National Academy Sciences.

The company recently reached a significant milestone in its efforts. The FDA cleared Quantum BioPharma’s Investigational New Drug (“IND”) application for Lucid-MS, allowing the company to move the candidate into phase 2 clinical trials. That stage of testing is designed to evaluate whether the drug is effective in treating MS in a controlled patient population and also allows for continued safety monitoring.

The global market for MS therapeutics reflects just how much is riding on finding better options. Precedence Research estimates that market at approximately $34.8 billion in 2025, with projections suggesting it could nearly double by 2035 as new mechanisms of action reach patients.

For the millions of people currently living with multiple sclerosis, and the hundreds of thousands more diagnosed each year, incremental progress in the lab eventually has to translate into new choices at the pharmacy. Quantum BioPharma is one of several companies working toward that goal, betting that protecting nerve tissue directly, rather than only quieting the immune system, could open a new chapter in how the disease is treated.

For more information, visit www.QuantumBioPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

• California’s SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force policies, but no policy can guarantee that verbal techniques will resolve an encounter.
• Wrap Technologies has completed a doctrine combining communication, recognition of resistance, positioning and remote restraint into a framework intended to operationalize de-escalation.
• The curriculum is undergoing independent validation ahead of an application for California POST certification, with digital delivery through Wrap Tactics planned if certification is obtained.

De-escalation has moved from a recommended practice to a formal part of law enforcement policy and training. California’s Senate Bill 230 required every law enforcement agency in the state to maintain a use-of-force policy incorporating de-escalation techniques, crisis intervention tactics and other alternatives to force when feasible. It also directed the Commission on Peace Officer Standards and Training (“POST”) to implement regular and periodic use-of-force instruction that includes tactical methods using time, distance, cover and concealment.

Those requirements establish what officers should attempt. They cannot make another person cooperate. An officer can communicate, persuade, slow the situation and issue lawful commands, yet the person involved may remain unable or unwilling to comply. Wrap Technologies Inc. (NASDAQ: WRAP) has developed a doctrine around what an officer can do when verbal efforts are not working but circumstances do not yet call for a traditional weapons-based response.

The Space Between 

Verbal de-escalation remains the foundation of the methodology WRAP announced on September 2. The doctrine combines communication, recognition of resistance, time, distance, tactical positioning and remote restraint within a single framework built around one question: what can an officer lawfully and tactically do when verbal de-escalation has reached its limit?

Conventional options move toward hands-on control or tools that operate through chemical, electrical or kinetic effects, each carrying greater risk for officers and the people they are attempting to restrain. WRAP positions the BolaWrap(R) 150 as an additional option within that gap: rather than relying solely on voluntary compliance, the methodology is intended to give an officer a physical capability that may help create the conditions for de-escalation.

The doctrine does not eliminate higher-force options. Officers retain the ability to transition to other lawful tools if the resistance or threat changes. WRAP calls the principle the “Lowest Reasonable Response”: identify an effective response appropriate to the resistance and circumstances, then continuously reassess the encounter.

Why the ATF Classification Matters

The doctrine follows ATF Ruling 2026-2, which determined that the BolaWrap(R) 150, as currently designed, is neither a firearm nor an “any other weapon” under federal law. The ruling identifies it as an instrument of restraint, while WRAP describes it as an instrument of restraint and rescue.

The handheld device deploys an eight-foot Kevlar tether around a person’s arms or legs from a range of 10 to 25 feet. It is designed to restrain without relying on electrical incapacitation, chemical irritants, pain compliance or a conventional impact projectile.

The ATF classification gives WRAP a foundation for developing doctrine around remote restraint as a distinct operational category. It does not determine whether any particular deployment is legally justified. That still depends on the facts of the encounter, applicable law and agency policy.

Addressing Behavioral and Mental Health Calls

WRAP sees the most relevant application in behavioral and mental health emergencies, where a person may be unable, rather than simply unwilling, to understand commands or respond to persuasion. An officer can follow accepted communication practices and still reach the end of the verbal playbook with the unresolved encounter.

Specialized Crisis Intervention Teams exist for these calls, but they cannot be present for every encounter. As WRAP puts it, the patrol officer is often the crisis intervention team until the crisis intervention team arrives.

The methodology is intended to bring crisis intervention principles closer to the point of first contact, with a defined sequence for recognizing crisis behavior, creating time and distance, considering remote restraint when appropriate, reassessing and transitioning to other lawful options if conditions change.

From Doctrine to Standardized Training

WRAP has submitted the curriculum for independent validation in preparation for applying for California POST certification. Neither validation nor certification is assured.

If certified, the curriculum would give California agencies a standardized methodology for incorporating the BolaWrap(R) 150 and operational de-escalation into patrol, crisis-response and agency training, distributed digitally through WRAP Tactics(TM), WRAP’s learning management system.

The Task Force 70 Foundation, a nonprofit law enforcement training organization, is supporting the doctrine, curriculum structure and instructor credentialing. WRAP believes recognized training could reduce adoption barriers by letting agencies evaluate the device alongside a defined operational framework, and digital delivery would add a recurring training component alongside device and cassette sales.

WRAP intends to use the California process as a model for seeking recognition in additional states. The company reports that BolaWrap(R) 150 has been adopted by more than 1,000 agencies in the United States and more than 60 countries.

De-escalation policies tell officers what they should attempt to accomplish. WRAP’s doctrine seeks to define what may come next when communication alone does not resolve the encounter. Whether it becomes a recognized operational standard will depend on validation, certification and its eventual performance in agency training and field use.

For more information, visit the company’s website at wrap.com.

NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP

About / Disclaimer

This article was produced by IBN Editorial Staff and is intended for informational purposes only. It is not investment advice and should not be relied upon as the basis for any investment decision. Statements attributed to Wrap Technologies, Inc. or its management, including any forward-looking statements regarding revenue growth, product development, or market opportunities, reflect the company’s views and are subject to risks and uncertainties; actual results may differ materially. Readers should conduct their own due diligence and consult a qualified professional. Additional company information is available at wrap.com.

• The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and changes in the mortgage and housing markets.
• The production is scheduled to begin distribution the week of Sept. 21 through BizTV, American Life Network and American Forces Network.
• The three networks have a combined potential audience of approximately 90 million viewers, according to Beeline.
• The program examines mortgage affordability, interest rates, housing inventory, alternative underwriting, automation and access to home equity.
• Beeline operates a digital mortgage and financial technology platform serving both homebuyers and real estate investors.
• The company’s strategy includes mortgage products for younger borrowers, including consumers seeking investment properties, as well as equity-focused products for homeowners with substantial accumulated home equity.

Beeline Holdings (NASDAQ: BLNE), a digital mortgage platform offering a more efficient path to homeownership, has partnered with Emmy Award-winning Loft 100 Studios on a new documentary-style production examining developments in the mortgage industry and changing approaches to homeownership (https://ibn.fm/RZsjX).

The 45-minute production, described as a “Bizumentary,” is scheduled to begin distribution during the week of September 21 through BizTV, American Life Network and American Forces Network. According to Beeline, the networks have a combined potential reach of approximately 90 million viewers. The company said the production could subsequently be considered for distribution through larger networks as it gains exposure.

The program examines several issues affecting the housing and mortgage markets, including affordability, interest rates, housing inventory, and changes in how consumers obtain mortgage financing and access home equity. It also features perspectives from business executives and other participants in the housing and financial-services markets.

The production was developed with Loft 100 Studios, a full-service production company whose team and productions have received Emmy recognition. The program combines documentary-style interviews and business commentary with an examination of technologies and financial products being developed within the mortgage market.

For Beeline, the production provides an opportunity to discuss its digital mortgage platform alongside broader changes taking place in housing finance. “The mortgage industry is at an important turning point,” said Nick Liuzza, CEO of Beeline. “Affordability remains a challenge, but innovation is creating new solutions. Non-traditional mortgage products are gaining popularity because they solve real problems for borrowers, while technology and automation are making financing faster, simpler and more accessible.”

Beeline operates through its wholly owned subsidiary, Beeline Loans Inc., providing mortgage financing for primary homebuyers and real estate investors. The company has built its lending platform around artificial intelligence and automation. Its technology includes Bob, an AI-powered mortgage assistant, and Hive, a proprietary mortgage production engine.

Beeline says its digital lending process can support loan closings in approximately 14 to 21 days. The company also reports a Net Promoter Score above 80, a metric used to measure customer satisfaction and willingness to recommend a service.

The company’s target market extends beyond consumers purchasing a primary residence. Beeline has developed mortgage products that address borrowers seeking real estate investment properties. This segment includes younger consumers who may be entering property ownership through investment rather than purchasing a home solely for personal use.

The approach is relevant as younger generations continue to face barriers to traditional homeownership. Data cited by the National Mortgage Professional indicated that 26.1% of Gen Z respondents and 54.9% of Millennials were homeowners in 2024. Limited access to mortgage financing and housing affordability have been among the factors affecting younger buyers.

Beeline has sought to use automation to shorten the initial mortgage qualification process. The company says its AI technology can provide an initial decision within approximately seven to eight minutes and give prospective borrowers an estimated 90% certainty regarding whether they qualify.

Homeowners who have accumulated significant equity represent another potential market for financial products. Beeline has identified approximately $10 trillion of U.S. home equity as an addressable opportunity and is developing solutions intended to give homeowners greater access to that capital.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at  https://ibn.fm/BLNE

• Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted trading environment
• The uplisting is one of several milestones the company has reported during the current financial year 2027, which began on April 1, 2026
• The company reported its Q1 2027 financial results, marking a 3% growth in revenue with a 57% increase in net income
• The company also acquired Meduvo LLC and Zoolzy and held its annual meeting of shareholders

Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to the OTCQB Venture Market effective September 17, 2026. The listing on OTCQB, an established public market for growth-stage and entrepreneurial companies, means ETST has met rigorous financial and reporting standards, undergone a verification process, and complied with strict management certification requirements (https://ibn.fm/0TQ91).

The uplisting is the latest milestone in fiscal year 2027, which began on April 1, 2026. During the intervening period, the company reported its Q1 2027 financial results, acquired Meduvo LLC (a compounding pharmacy) and Zoolzy LLC, and held its annual meeting of shareholders. 

The Q1 results reflected steady compounding progress and the inherent operating leverage within ETST’s business model: revenue grew 3% to $9.0 million, gross profit rose 3.1% to $6.3 million, and net income jumped 57% to $715,697, with all key operating subsidiaries remaining profitable (https://ibn.fm/V8OXi).

According to Giorgio R. Saumat, CEO and Chairman of the Board, the company maintained internal standards and continues to actively focus on driving even greater operational efficiencies. These standards are also evident externally, especially with the recent uplisting to the OTCQB market, which emphasizes elevated transparency and aims to provide investors with a trusted trading environment.

Moreover, ETST acquired Zoolzy, a wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products (https://ibn.fm/VILA1). In his address at the Annual Meeting, Mr. Saumat said the acquisition represented the company’s move “to unlock a whole new business”: the lucrative animal health market.

Zoolzy creates a new supply line that supports the formulation of unique, flavored, and easy-to-administer veterinary therapeutics. It also enables Earth Science Tech and its network of compounding pharmacies to acquire APIs for human medication; they will be able to secure raw materials as well as new, highly sought-after APIs at competitive wholesale prices that increase profit margins. 

The company also held its Annual Meeting of Stockholders on August 31, 2026. During the meeting, shareholders authorized the Board to pursue a reverse stock split, if deemed necessary, to support plans to uplist to Nasdaq or NYSE. The stockholders also ratified a plan to retire the current dual-class voting structure by negotiating the sale of Series B Preferred Stock, with the execution of this proposal aiming to attract institutional capital. Moreover, the shareholders approved the appointment of an independent registered public accounting firm, the re-election of seven director nominees, and a new non-dilutive executive compensation framework. Mr. Saumat and management also fielded questions (https://ibn.fm/C8zGp).

The milestones reported so far represent the company’s relentless focus on maximizing shareholder value. The company remains committed to optimizing the operational frameworks of its holdings to support scalable, sustainable expansion.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies.
• The company entered the NASDAQ market in June 2026 following its completed business combination with Voyager Acquisition Corp., giving VERAXA access to the U.S. public markets as it advances its development programs.
• BiTAC is designed as an “AND-gated” therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated.
• VERAXA has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in June.
• Recent corporate developments include the appointment of Raju Willener as CFO and Christoph Erkel, Ph.D., as chief scientific officer, adding financial and antibody-development expertise.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is entering a new phase of development following its transition to the NASDAQ market and a series of scientific and corporate milestones that have expanded the company’s focus around its proprietary BiTAC(R) platform. The Swiss biotechnology company began trading on the NASDAQ Capital Market under the ticker VRXA in June following the completion of its business combination with Voyager Acquisition Corp. The transaction was accompanied by financing arrangements that included a $27.5 million senior secured note and a securities purchase agreement for up to $50 million. The company said the financing was intended to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. Since then, VERAXA has continued building the infrastructure around its drug-development strategy. Most recently, the company appointed Raju Willener as chief financial officer. Willener brings more than three decades of experience spanning investment banking, corporate finance, asset management and capital markets. Before joining VERAXA, he was director of corporate development at Exentis Group AG and subsequently became its CFO in 2025. Earlier in his career, he held senior positions involving investment portfolios exceeding CHF 30 billion in assets under management. The appointment comes as VERAXA attempts to move its technology from proof-of-concept work toward a broader therapeutic pipeline. At the center of that effort is BiTAC, short for Bi-targeted Tumor-Associated Cytotoxicity. The technology differs from conventional bispecific antibodies by separating its targeting functions into two complementary molecules. The intended mechanism is conditional. Each component by itself should have limited cytotoxic activity, while simultaneous engagement of both targets on the same tumor cell is designed to establish the active therapeutic mechanism. VERAXA describes this as an “AND-gated approach.” For T-cell engagers, the architecture is intended to restrict activation of T cells to cancer cells carrying both selected targets. The company’s stated objective is to improve tumor selectivity and potentially widen the therapeutic window. The concept has already generated early experimental data. At the 2026 American Association for Cancer Research Annual Meeting, VERAXA presented results from its most advanced BiTAC-TCE program. According to the company, the candidate showed activity against cells carrying both target molecules while sparing cells expressing only one target. VERAXA also reported in-vivo results showing comparable efficacy to a conventional TCE alongside an improved safety profile. VERAXA has also extended the BiTAC concept into antibody-drug conjugates, or ADCs. In June, the company reported an in-vitro proof of concept for its BiTAC-ADC platform and said laboratory testing demonstrated selective activity against breast-cancer cells, including dose-dependent killing in three-dimensional tumor spheroids. The company subsequently used the data in discussions around potential partnering opportunities. That dual-platform strategy places VERAXA within two active areas of oncology research. ADCs combine an antibody with a potent cytotoxic payload, allowing targeted delivery of cancer-killing compounds. The technology has attracted significant pharmaceutical investment as developers seek to improve tumor targeting, payload delivery and tolerability. Grand View Research estimates that the global ADC market could reach $32.11 billion by 2033, compared with a projected compound annual growth rate of 10.49% from 2025 through 2033. VERAXA is developing additional technologies around ADC construction, including site-specific conjugation, click chemistry, hydrophilic payload-linker systems and tumor-selective approaches to payload activation. These technologies provide a broader development base beyond BiTAC itself. The company’s pipeline also includes VX-A901, a clinical-stage monoclonal antibody targeting FLT3 for acute myeloid leukemia. The program has generated Phase I clinical data, while VERAXA has said it intends to pursue an out-licensing strategy as its development emphasis increasingly shifts toward conditionally active, dual-targeting modalities. Alongside the pipeline, VERAXA has been strengthening its scientific organization. The company appointed Christoph Erkel, Ph.D., as chief scientific officer, while recent regulatory work with Germany’s Paul-Ehrlich-Institute provided feedback on the proposed nonclinical development strategy for its BiTAC-TCE program. VERAXA has also expanded its intellectual-property portfolio around its technology platforms. Another recent development has broadened the company’s technology interests beyond ADCs and TCEs. In August, VERAXA and Secarna Pharmaceuticals announced an in-vitro proof-of-concept milestone in an antibody-oligonucleotide conjugate alliance, combining VERAXA’s conjugation capabilities with Secarna’s oligonucleotide technology. The company has also been expanding intellectual-property protection. In July, VERAXA reported more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families, with additional applications covering BiTAC-TCE and BiTAC-ADC technologies. For more information, visit the company’s website at www.Veraxa.com. NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

PAID ADVERTISEMENT. This article is a paid advertisement for BOXABL Inc. (Nasdaq: BXBL), distributed by NetworkNewsWire (“NNW”), a division of InvestorBrandNetwork (“IBN”). IBN has been compensated for advertising and digital media services related to BOXABL Inc. Readers should review the full disclaimer at the foot of this article before making any investment decision.

• BOXABL, transforming the housing market, has launched a new initiative that calls for companies across the housing supply chain, including landholders, operators, and technology owners, to explore partnerships, mergers, acquisitions, and other combinations.
• The company is considering flexible transaction structures, including cash, stock, or combinations of the two, subject to due diligence and definitive agreements.
• BOXABL is seeking capabilities ranging from manufacturing and land development to installation, logistics, financing, automation, and software.
• The initiative broadens BOXABL’s strategy beyond manufacturing modular homes toward assembling a more integrated housing platform.
• The company’s Casita folding modular unit remains its flagship product, while its technology is being developed for larger and connectable housing configurations.

BOXABL (NASDAQ: BXBL), an innovative technology company transforming the housing market with its modular building systems, is opening its corporate development strategy to potential combinations across the housing industry, launching a new section of its website designed to attract companies, landholders, operating talent and technology owners that could contribute to a larger factory-built housing platform (https://ibn.fm/5B7yQ).

The company announced that it was evaluating potential mergers, acquisitions, joint ventures, land contributions, talent additions and technology or intellectual-property transactions. BOXABL is also inviting broader M&A proposals where a combination could accelerate its efforts to make housing more affordable at mass-production scale.

The initiative arrives less than a month after BOXABL began trading on NASDAQ on July 20 following its business combination with FG Merger II Corp. The new public-market status gives investors another way to assess how the company intends to move from developing modular construction technology toward building a broader housing ecosystem.

BOXABL’s new mergers and partnerships initiative identifies four broad categories of potential opportunities: companies, land, talent and inventions.

The company said it is interested in manufacturers, installers, dealers, lenders, haulers and suppliers of different sizes. It is also looking for raw, entitled and infill land, as well as acreage that could support future housing developments.

Talent is another target. BOXABL is seeking operators with experience in building, moving, selling and financing housing. The company has characterized operating experience as an important reason for pursuing deals, reflecting an effort to acquire capabilities rather than simply add physical assets.

The fourth category covers technology and intellectual property. BOXABL is inviting proposals involving patents, prototypes, tooling, manufacturing processes and software that could address bottlenecks within affordable housing. That includes technologies designed to improve panel systems or increase factory-line efficiency.

The strategy reflects a practical constraint facing factory-built housing companies: producing a home is only one part of the overall housing process.  A modular unit still needs land, transportation, installation, site work, financing and a sales channel before it becomes a completed housing transaction. BOXABL’s M&A initiative is therefore aimed at potential gaps throughout that chain.

“Housing is too expensive right now, and every year we spend inventing something that already exists is a year homes stay unaffordable,” said Galiano Tiramani, BOXABL Founder and Co-CEO. “If someone has already solved a piece of it, the fastest path is to bring them in — not to start over in-house and hope we catch up.”

The company specifically identified factories and fabrication facilities, developers and landholders, site-work contractors, transportation and logistics operators, lenders, sales and dealer networks, automation providers, software companies and materials suppliers as areas of interest.

BOXABL said potential transactions would be assessed individually. Structures could involve cash, stock or a combination, depending on the circumstances of a particular deal. Any transaction would remain subject to due diligence, applicable approvals, and entry into definitive agreements.

BOXABL’s flagship Casita is a 361-square-foot studio-style modular home with a kitchen, bathroom and utilities. The unit is manufactured in a compact configuration and designed to unfold on site, with BOXABL stating that the installation process can take less than an hour under appropriate conditions.

The company also plans to offer the smaller Baby Box, while also developing larger configurations. Its modular architecture is intended to allow units to be connected and stacked, creating larger residences and structures.

That design is central to BOXABL’s effort to move beyond a single modular home product. The company has identified potential applications including single-family housing, townhomes, multifamily developments and other structures that can be assembled from standardized modules.

BOXABL’s approximately 400,000-square-foot Las Vegas manufacturing facility is part of that strategy. The company continues working to increase manufacturing efficiency.

The company is also incorporating automation and artificial intelligence into its production processes. The objective is to make housing production more repeatable and potentially less dependent on the variable labor requirements associated with conventional site-built construction.

BOXABL has previously estimated the U.S. housing opportunity at approximately $2.2 trillion, based on an estimated need for more than 5 million additional homes. The company has also estimated that the modular and manufactured housing segment represents an approximately $36 billion annual opportunity.

For more information, visit the company’s website at www.Boxabl.com.

NOTE TO INVESTORS: The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL

Cautionary Note Regarding the Business Combination and Capital Structure. BOXABL Inc. became a publicly traded company through a business combination with FG Merger II Corp., a special purpose acquisition company, completed in July 2026, with the shares beginning trading on the Nasdaq Stock Market under the symbol BXBL on July 20, 2026. Companies that become public through special purpose acquisition transactions may be subject to risks including share price volatility, dilution, limited operating history as a public company, and redemption-related capital reductions. In July 2026 the Company filed a universal mixed shelf registration statement that would permit it to offer up to $500,000,000 of securities over time; any such issuance would be dilutive to existing holders. References to capital raised since inception and to the number of investors are as disclosed by the Company. Readers should review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov, including its periodic reports, in full.

Cautionary Note Regarding Forward-Looking Statements. This publication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including projections of market opportunity and market share, estimates of customer adoption, projections of development and commercialization costs and timelines, expectations regarding the Company’s ability to execute its business model, the deployment of the Casita, the development and potential production of the Baby Box and of stackable and connectable modules, the pursuit of additional state regulatory approvals, expectations concerning relationships with customers, developers, strategic partners, suppliers, governments and regulatory bodies, and the potential for future projects. Such statements are generally identified by words such as “plan”, “project”, “will”, “estimate”, “intend”, “expect”, “believe”, “target”, “continue”, “could”, “may”, “might”, “possible”, “potential” or “predict”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual circumstances, events, or results to differ materially, including manufacturing, supply chain, permitting, regulatory, financing, dilution, listing, competitive and market risks, and other risks identified in the Company’s filings with the Securities and Exchange Commission. Do not place undue reliance on such statements. The forward-looking statements in this publication are made as of the date above and IBN undertakes no obligation to update them.

Full Disclaimer. NetworkNewsWire (“NNW”) is a division of InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company. IBN has been compensated for advertising and digital media services for BOXABL Inc. This publication is for informational purposes only and is not, and should not be construed as, a research report, investment advice, or a recommendation to buy or sell any security. The information contained herein is believed to be reliable but no guarantee can be made as to its accuracy or completeness. Neither IBN nor NNW is registered as an investment adviser or broker-dealer. Readers should review BOXABL Inc.’s filings with the U.S. Securities and Exchange Commission and consult with a licensed financial advisor before making any investment decision. Please see the full terms of use and disclaimers applicable to all content provided by IBN, wherever published or re-published, at https://IBN.fm/Disclaimer.